Combination of encorafenib and binimetinib followed by ipilimumab and nivolumab versus ipilimumab and nivolumab in patients with advanced melanoma with BRAFV600E or BRAFV600K mutations (EBIN): an international, open-label, randomised, controlled, phase 2 study
Caroline Robert(Inserm), Alexander C. J. van Akkooi(The University of Sydney), S. Monestier(Hôpital de la Timone), Sandrine Mansard(Centre Hospitalier Universitaire de Clermont-Ferrand), Célèste Lebbé(Inserm), Xavier Durando(Inserm), Felix Boakye Oppong(European Organisation for Research and Treatment of Cancer), Michal Kiciński(European Organisation for Research and Treatment of Cancer), Philippe Saïag(Université de Versailles Saint-Quentin-en-Yvelines), Elisa Funck‐Brentano(Institut Mondor de Recherche Biomédicale), Caroline Gaudy‐Marqueste(Aix-Marseille Université), F. Aubin(Centre Hospitalier Universitaire de Besançon), Mona Amini‐Adlé(Centre Léon Bérard), Émilie Routier(Université Paris-Saclay), Anne-Sophie Govaerts(European Organisation for Research and Treatment of Cancer), Caroline Dutriaux(Centre Hospitalier Universitaire de Bordeaux), Eva Muñoz‐Couselo(Vall d'Hebron Hospital Universitari), Florent Grange(Hôpital Lyon Sud), Emanuel Bührer(European Organisation for Research and Treatment of Cancer), Paul Lorigan(Manchester Academic Health Science Centre), Stéphane Dalle(Hospices Civils de Lyon), Sorilla Mary-Prey(Centre Hospitalier Universitaire de Bordeaux), Laurent Mortier, M. Mandala(University of Perugia), Michelangelo Russillo(National Cancer Institute), Barouyr Baroudjian(Hôpital Saint-Louis), Paolo A Ascierto(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Alexander Eggermont(University Medical Center Utrecht), Jean‐Luc Perrot(Centre Hospitalier Universitaire de Saint-Étienne), Eve‐Marie Neidhardt(Centre Léon Bérard), Bastian Schilling(Goethe University Frankfurt), Leen Wijnen(European Organisation for Research and Treatment of Cancer), Ana Arance(Hospital Clínic de Barcelona)
Cited by 10
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
|Science|2017|5.4k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Combined Vemurafenib and Cobimetinib in <i>BRAF</i> -Mutated Melanoma
|New England Journal of Medicine|2014|2k
Adjuvant Dabrafenib plus Trametinib in Stage III<i>BRAF</i>-Mutated Melanoma
|New England Journal of Medicine|2017|1.5k